ATE173740T1 - Antikoerper mit geaenderter zielrichtung - Google Patents
Antikoerper mit geaenderter zielrichtungInfo
- Publication number
- ATE173740T1 ATE173740T1 AT94926336T AT94926336T ATE173740T1 AT E173740 T1 ATE173740 T1 AT E173740T1 AT 94926336 T AT94926336 T AT 94926336T AT 94926336 T AT94926336 T AT 94926336T AT E173740 T1 ATE173740 T1 AT E173740T1
- Authority
- AT
- Austria
- Prior art keywords
- target
- antibodies
- specificity
- binding
- cells
- Prior art date
Links
- 230000027455 binding Effects 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939319969A GB9319969D0 (en) | 1993-09-22 | 1993-09-22 | Binding proteins iv |
| PCT/GB1993/002492 WO1994013804A1 (en) | 1992-12-04 | 1993-12-03 | Multivalent and multispecific binding proteins, their manufacture and use |
| GB9412166A GB9412166D0 (en) | 1993-09-22 | 1994-06-17 | Retargetting antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE173740T1 true ATE173740T1 (de) | 1998-12-15 |
Family
ID=26303591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94926336T ATE173740T1 (de) | 1993-09-22 | 1994-09-16 | Antikoerper mit geaenderter zielrichtung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6589527B1 (de) |
| EP (1) | EP0720624B1 (de) |
| JP (1) | JPH09503759A (de) |
| AT (1) | ATE173740T1 (de) |
| AU (1) | AU680685B2 (de) |
| CA (1) | CA2169620A1 (de) |
| DE (1) | DE69414870T2 (de) |
| DK (1) | DK0720624T3 (de) |
| ES (1) | ES2126145T3 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| WO2001079481A2 (en) * | 2000-04-17 | 2001-10-25 | Dyax Corp. | Methods of constructing display libraries of genetic packages for members of a diverse family of peptides |
| EP1360288B1 (de) | 2000-12-18 | 2011-02-16 | Dyax Corp. | Gerichtete bibliotheken die genetisch verpackt sind |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040067532A1 (en) * | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| EP2298815B1 (de) | 2005-07-25 | 2015-03-11 | Emergent Product Development Seattle, LLC | B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen |
| ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
| KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
| EP2197491A4 (de) | 2007-09-04 | 2011-01-12 | Univ California | Hochaffine anti-prostata-stammzell-antigen-(psca-) antikörper gegen krebs und zum nachweis von krebs |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US9873957B2 (en) * | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
| WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| CA2968164C (en) | 2008-04-24 | 2019-08-20 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
| US20110082054A1 (en) * | 2009-09-14 | 2011-04-07 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
| EP2593594B1 (de) | 2010-07-16 | 2017-09-27 | Adimab, LLC | Antikörperbibliotheken |
| CA3202536A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla, Llc | Multi-specific monoclonal antibodies |
| SG10202002577XA (en) | 2015-09-21 | 2020-04-29 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
| CN111500534B (zh) * | 2016-07-11 | 2022-11-29 | 山东亚大药业有限公司 | 分离纯化胎儿有核红细胞的试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US6329507B1 (en) | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
| CA2150262C (en) * | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
-
1994
- 1994-09-16 DK DK94926336T patent/DK0720624T3/da active
- 1994-09-16 ES ES94926336T patent/ES2126145T3/es not_active Expired - Lifetime
- 1994-09-16 CA CA002169620A patent/CA2169620A1/en not_active Abandoned
- 1994-09-16 JP JP7509628A patent/JPH09503759A/ja not_active Ceased
- 1994-09-16 AT AT94926336T patent/ATE173740T1/de not_active IP Right Cessation
- 1994-09-16 DE DE69414870T patent/DE69414870T2/de not_active Expired - Lifetime
- 1994-09-16 AU AU76214/94A patent/AU680685B2/en not_active Ceased
- 1994-09-16 EP EP94926336A patent/EP0720624B1/de not_active Expired - Lifetime
-
1996
- 1996-03-22 US US08/621,038 patent/US6589527B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0720624A1 (de) | 1996-07-10 |
| DK0720624T3 (da) | 1999-08-09 |
| ES2126145T3 (es) | 1999-03-16 |
| AU7621494A (en) | 1995-04-10 |
| EP0720624B1 (de) | 1998-11-25 |
| DE69414870D1 (de) | 1999-01-07 |
| CA2169620A1 (en) | 1995-03-30 |
| DE69414870T2 (de) | 1999-05-12 |
| JPH09503759A (ja) | 1997-04-15 |
| US6589527B1 (en) | 2003-07-08 |
| AU680685B2 (en) | 1997-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE173740T1 (de) | Antikoerper mit geaenderter zielrichtung | |
| Cobbold et al. | Therapeutic potential of monovalent monoclonal antibodies | |
| DK0554344T3 (da) | Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor | |
| PT712307E (pt) | Metodos para controlo da populacao de celulas b | |
| NZ331978A (en) | Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system | |
| ES8606655A1 (es) | Un procedimiento de inmunoensayo | |
| CA2060544A1 (en) | Recombinant antibodies specific for a growth factor receptor | |
| FI864037A0 (fi) | Monoklonala antikroppar mot broestkraefta hos maenniska. | |
| KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
| PT100637A (pt) | Receptor ctla4 e metodos para a sua utilizacao | |
| CU22615A1 (es) | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos | |
| HUP9802401A2 (hu) | Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására | |
| AU6054398A (en) | Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope | |
| ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
| MY111682A (en) | Altered antibodies and their preparations. | |
| DK113389D0 (da) | Monoklonale antistoffer | |
| GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
| NO986088D0 (no) | Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi | |
| EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
| CA2068222A1 (en) | Monoclonal antibodies | |
| ATE77243T1 (de) | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. | |
| TR199801769T2 (xx) | D���k reg�lasyona diren�li C3 d�n��t�r�c�ler. | |
| Aase et al. | The use of a hapten-Fab conjugate to sensitive target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity | |
| Ditzel et al. | Preparation of antigen-binding monomeric and half-monomeric fragments from human monoclonal IgM antibodies against colorectal cancer-associated antigens | |
| DK0513565T3 (da) | Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |